Supplementary Table 1

Statistical analysis comparing group values before and after one bevacizumab infusion

Parameter	Before treatment	After treatment	*P*-value
Blood flow	81 ±16	53 ± 9	0.005
Blood volume	6.8 ± 2.1	5.0 ± 0.94	0.03
PS product	14 ± 2	12.9 ± 3.1	0.2
Microvascular density	13.0 ± 3.2	6.9 ± 1.8	0.003
α−SMA coverage	9.9 ± 3.8	17.8 ± 1.5	0.09[a]
FDG uptake	5.6 (1.9 – 12.9)	4.1 (2.9 – 13.8)	0.8[c]
Interstitial fluid pressure	15.0 ± 2.0	4.0 ± 2.2	0.01
CECs / WBC	0.19 (0.006 - 0.029)	0.009 (0.004 - 0.019)	0.04[b]
Progenitor/stem cells / WBC	0.0011 (0.0006 - 0.206)	0.0010 (0.0005 - 0.075)	0.04[b]

[a]The difference in the fraction of α-SMA positive vessels in patient two was identified as an outlier by the Extreme Studentized Deviate (ESD) test. Paired t-test analyses of the mean values that excluded the data of patient two (6.4±1.9 and 17.8±1.9 for before and after treatment, respectively) had a $P < 0.001$.

[b]Wilcoxon signed-rank test.

[c] Note that at presurgery, the uptake was decreased significantly ($P<0.01$), compared to both these two timepoints.